Kairos Pharma
KAPA0.29531.24% ( -0.0037 )
Kairos Pharma (KAPA)
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers thera...
- Open
- 0.2929
- High
- 0.2999
- Low
- 0.2862
- Prev. Close
- 0.2990
- Volume
- 133.87K
- Turnover
- 39.19K
- Avg Price
- 0.2928
- Bid/Ask Ratio
- --
- Amplitude
- 4.58%
- 52wk High
- 2.1100
- Volume Ratio
- 0.02
- Turnover Ratio
- 1.00%
Kairos Pharma Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$7.002270.47%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy50.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Jul 27 at 12:35 PM
Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12
- StockTitan · Jul 21 at 11:35 PM
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer | KAPA Stock News
- benzinga_article · Jul 17 at 07:05 AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
- WorldPharmaceuticals · Jul 16 at 04:46 AM
Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
- benzinga_article · Jul 16 at 01:51 AM
Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving?
- PUBT · Jul 15 at 07:32 AM
Kairos Pharma reports interim Phase 1 safety data for ENV-105 with Tagrisso in EGFR-mutated lung cancer
